---
title: A Study of LY2835219 in Healthy Participants
nct_id: NCT02059148
overall_status: COMPLETED
phase: PHASE1
sponsor: Eli Lilly and Company
study_type: INTERVENTIONAL
primary_condition: Healthy Volunteers
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02059148.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02059148"
ct_last_update_post_date: 2019-01-07
last_seen_at: "2026-05-12T06:44:19.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study of LY2835219 in Healthy Participants

**Official Title:** Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects

**NCT ID:** [NCT02059148](https://clinicaltrials.gov/study/NCT02059148)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 24
- **Lead Sponsor:** Eli Lilly and Company
- **Conditions:** Healthy Volunteers
- **Start Date:** 2014-02
- **Completion Date:** 2014-08
- **CT.gov Last Update:** 2019-01-07

## Brief Summary

Participants in this study will receive 3 single oral doses of LY2835219 at least 14 days apart. One dose will be given with a standard meal, one dose with a high-fat meal and one dose without food. The study will evaluate the effects of the standard and high-fat meals on how much drug gets into the bloodstream. Side effects will be documented. This study is approximately 43 days, not including screening. Screening is required within 28 days prior to the start of the study.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy sterile males or surgically sterile or postmenopausal females
* Have a body mass index (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive, at screening
* Are able to eat a high-fat, high-calorie meal

Exclusion Criteria:

* Participated in a clinical trial involving investigational product within 30 days
* Abnormal blood pressure
* Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
* Have donated blood of more than 500 milliliter (mL) within the last month
* Show evidence of human immunodeficiency virus, hepatitis B or hepatitis C
```

## Arms

- **LY2835219 Standard** (EXPERIMENTAL) — Single oral dose of LY2835219 given with a standard meal in one of three study periods.
- **LY2835219 Fasted** (EXPERIMENTAL) — Single oral dose of LY2835219 given with no food in one of three periods.
- **LY2835219 High-Fat** (EXPERIMENTAL) — Single oral dose of LY2835219 given with a high fat meal in one of three periods.

## Interventions

- **LY2835219** (DRUG) — Administered orally.

## Primary Outcomes

- **Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219 Fasted vs. High-Fat Arms** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_
- **Pharmacokinetics: Area Under the Concentration Curve (0-t Last) [AUC(0-t Last)] of LY2835219 Fasted vs. High-Fat Arms** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_
- **Pharmacokinetics: Time of Maximum Observed Concentration (Tmax) of LY2835219 Fasted vs. High-Fat Arms** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_

## Secondary Outcomes

- **Pharmacokinetics: Cmax of LY2835219 in Standard Meal Arm** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_
- **Pharmacokinetics: AUC(0-tlast) of LY2835219 in Standard Meal Arm** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_
- **Pharmacokinetics: Tmax of LY2835219 in Standard Meal Arm** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_
- **Pharmacokinetics: Area Under the Concentration Curve (AUC 0-t Last) of LSN3106726 (M20)** _(time frame: Predose, 0.5,1,2,3,4,6,8,10,12,24,48,72,96,120,144,168,192 hours post-LY2835219 dose in each period)_

## Locations (1)

- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dallas, Texas, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician.|dallas|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02059148.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02059148*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*